SBIR-STTR Award

Commercialization of Cavitation-Enhancing Nanodroplets for DNA Sample Fragmentation in NGS Applications
Award last edited on: 9/21/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$2,297,934
Award Phase
2
Solicitation Topic Code
396
Principal Investigator
Sandeep Kasoji

Company Information

Triangle Biotechnology Inc

303 West Barbee Chapel Road
Chapel Hill, NC 27517
   (704) 807-4118
   info@trianglebio.com
   www.trianglebio.com
Location: Single
Congr. District: 04
County: Orange

Phase I

Contract Number: 1R43CA232902-01
Start Date: 7/5/2018    Completed: 6/30/2019
Phase I year
2018
Phase I Amount
$298,530
More than 80,000 laboratories globally are working on biological sample processing, with a rapidly growing focus on next-generation sequencing (NGS) technologies. The milestone of the $1000 human genome sequence has established NGS as the gold standard technology for personalized/precision medicine and diagnostics. Genetic testing kids are now as readily available as pregnancy test kids, and advances in genetic analysis, gene therapy, and genetic modification promise in the 21st century to parallel the development of transistors and integrated circuits in the 20th century. The challenge is that technology for preparing biological samples for sequencing has not maintained a similar rapid advancement to gene sequencing. Fragmentation of DNA randomly without bias is an essential, but difficult step in the preparation of genomic DNA for NGS applications. A narrow range of DNA fragment lengths is required for sequencing, and inefficient or inconsistent fragmentation will result in incomplete or excluded reads, corrupting the sequencing. Acoustic sonication, which fragments DNA through cavitation, is the gold standard for DNA fragmentation. However, our customer discover interviews have reinforced that this is a significant pain point in their sample preparation process due to its low throughput and challenging consistency, particularly for industry developing large-scale sequencing efforts. Our NCI IMAT-funded academic co-founders have invented a novel approach that overcomes throughput and consistency bottlenecks in sample preparation for next-generation sequencing (NGS) technologies, based on our preliminary data. We have invented a novel nanodroplet reagent that enhances cavitation from an acoustic sonicator, and greatly improves consistency and reduces time and acoustic power requirements for DNA fragmentation. Triangle Biotechnology has licensed the patents describing the cavitation enhancing technology. With this SBIR, we will establish feasibility of this novel reagent, and perform key research, development, and proof of concept studies required prior to commercialization. Success of this project will enable a novel commercial solution for addressing market pain points: substantially improving throughput and consistency of DNA fragmentation for NGS sample preparation while reducing cost.

Project Terms:
Acoustics; Address; base; Base Pairing; Bathing; Biological; biological preparation; Biotechnology; commercialization; cost; Data; Development; Devices; Diagnostic; DNA; DNA Fragmentation; Due Process; Enhancement Technology; Face; Fluorocarbons; Formulation; Funding; gene therapy; Genes; Genetic; genetic analysis; Genetic screening method; Genome; Genomic DNA; Genomics; Gold; Health Technology; High-Throughput Nucleotide Sequencing; Human Genome; improved; Industry; innovation; interest; Interview; Laboratories; Large-Scale Sequencing; Legal patent; Length; Letters; Modification; nanoDroplet; next generation sequencing; novel; novel strategies; Pain; parallel processing; personalized diagnostics; Phase; precision medicine; Pregnancy Tests; Preparation; Process; programs; Protocols documentation; Public Health; Reagent; Research; research and development; Research Institute; Sampling; Small Business Innovation Research Grant; Sonication; success; Technology; Therapeutic; Time; tool; Transistors; Ultrasonics; Water;

Phase II

Contract Number: 2R44CA232902-02A1
Start Date: 7/5/2018    Completed: 8/31/2022
Phase II year
2020
(last award dollars: 2021)
Phase II Amount
$1,999,404

The completion of the Human Genome Project has established NGS as the gold standard technology for personalized/precision medicine and diagnostics. Genetic testing kits are now as readily available as pregnancy test kits, and advances in genetic analysis, gene therapy, and genetic modification in the 21st century promise to parallel the development of transistors and integrated circuits in the 20th century. The challenge is that technology for preparing biological samples for sequencing has not maintained a similar rapid advancement to gene sequencing. Fragmentation of DNA randomly without bias is an essential, but difficult step in the preparation of genomic DNA for NGS applications. A narrow range of DNA fragment lengths is required for sequencing, and inefficient or inconsistent fragmentation will result in incomplete or excluded reads, corrupting the sequencing. Sonication, which fragments DNA through cavitation, is the gold standard for DNA fragmentation. However, our customer discover interviews have reinforced that this is a significant pain point in their sample preparation process due to its low throughput and inconsistency, particularly for industry developing large-scale sequencing efforts. We have invented a novel nanodroplet reagent that enhances cavitation from an acoustic sonicator, and greatly improves consistency and reduces time and acoustic power requirements for DNA fragmentation. Triangle Biotechnology has licensed the patents describing this cavitation enhancing technology. We have achieved milestones proposed in Phase I, demonstrating product and technical feasibility. With this SBIR Phase II, we will perform key R&D tasks, product development, and validation studies to prepare for commercialization. Success of this project will enable a novel commercial solution for addressing market pain points: substantially improving throughput and consistency of DNA fragmentation for NGS sample preparation while reducing cost.

Public Health Relevance Statement:
RELEVANCE TO PUBLIC HEALTH Technology for preparing biological samples for next generation sequencing (NGS) faces several bottlenecks which have become significant pain points. Our innovative cavitation enhancing nanodroplet reagent overcomes throughput and consistency bottlenecks in sample preparation for (NGS) technologies. With this SBIR Phase II, we will perform key research, development, and validation studies required for commercialization.

Project Terms:
Acoustics; Address; Base Pairing; Bathing; Biological; Biotechnology; Cell Line; commercialization; cost; design; Development; Digestion; DNA; DNA Fragmentation; DNA Sequencing Facility; Due Process; Enhancement Technology; Equipment; Exclusion; exome; Exposure to; Face; Fluorocarbons; Freezing; gene therapy; Generations; Genes; Genetic; genetic analysis; genetic testing; Genomic DNA; Genomics; Gold; Head; Health Technology; human DNA; Human Genome Project; improved; Individual; Industry; Industry Standard; innovation; insertion/deletion mutation; instrument; Interview; Large-Scale Sequencing; Legal patent; Length; Libraries; Methods; Modification; nanoDroplet; next generation sequencing; novel; Output; Pain; Performance; personalized diagnostics; Phase; Positioning Attribute; precision medicine; Pregnancy Tests; Preparation; Price; product development; Production; Protocols documentation; prototype; Public Health; Quality Control; Reagent; Reproducibility; research and development; Risk; Sales; Sampling; scale up; Ships; Signal Transduction; Single Nucleotide Polymorphism; Small Business Innovation Research Grant; Sonication; Standardization; success; Technology; Testing; Time; Transistors; Tube; Ultrasonics; Validation; validation studies; whole genome; Work